°£Æí°áÁ¦, ½Å¿ëÄ«µå û±¸ÇÒÀÎ
ÀÎÅÍÆÄÅ© ·Ôµ¥Ä«µå 5% (76,000¿ø)
(ÃÖ´ëÇÒÀÎ 10¸¸¿ø / Àü¿ù½ÇÀû 40¸¸¿ø)
ºÏÇǴϾð ·Ôµ¥Ä«µå 30% (56,000¿ø)
(ÃÖ´ëÇÒÀÎ 3¸¸¿ø / 3¸¸¿ø ÀÌ»ó °áÁ¦)
NH¼îÇÎ&ÀÎÅÍÆÄÅ©Ä«µå 20% (64,000¿ø)
(ÃÖ´ëÇÒÀÎ 4¸¸¿ø / 2¸¸¿ø ÀÌ»ó °áÁ¦)
Close

¼Òµ¿¹° ÇǺÎÇÐ ½ÃÅ©¸´

¼Òµæ°øÁ¦

2013³â 9¿ù 9ÀÏ ÀÌÈÄ ´©Àû¼öÄ¡ÀÔ´Ï´Ù.

ÆǸÅÁö¼ö 12
?
ÆǸÅÁö¼ö¶õ?
»çÀÌÆ®ÀÇ ÆǸŷ®¿¡ ±â¹ÝÇÏ¿© ÆǸŷ® ÃßÀ̸¦ ¹Ý¿µÇÑ ÀÎÅÍÆÄÅ© µµ¼­¿¡¼­ÀÇ µ¶¸³ÀûÀÎ ÆǸŠÁö¼öÀÔ´Ï´Ù. ÇöÀç °¡Àå Àß Æȸ®´Â »óÇ°¿¡ °¡ÁßÄ¡¸¦ µÎ¾ú±â ¶§¹®¿¡ ½ÇÁ¦ ´©Àû ÆǸŷ®°ú´Â ´Ù¼Ò Â÷ÀÌ°¡ ÀÖÀ» ¼ö ÀÖ½À´Ï´Ù. ÆǸŷ® ¿Ü¿¡µµ ´Ù¾çÇÑ °¡ÁßÄ¡·Î ±¸¼ºµÇ¾î ÃÖ±ÙÀÇ À̽´µµ¼­ È®Àνà À¯¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇØ´ç Áö¼ö´Â ¸ÅÀÏ °»½ÅµË´Ï´Ù.
Close
°øÀ¯Çϱâ
Á¤°¡

80,000¿ø

  • 80,000¿ø

    2,400P (3%Àû¸³)

ÇÒÀÎÇýÅÃ
Àû¸³ÇýÅÃ
  • S-Point Àû¸³Àº ¸¶ÀÌÆäÀÌÁö¿¡¼­ Á÷Á¢ ±¸¸ÅÈ®Á¤ÇϽŠ°æ¿ì¸¸ Àû¸³ µË´Ï´Ù.
Ãß°¡ÇýÅÃ
¹è¼ÛÁ¤º¸
  • 3/28(¸ñ) À̳» ¹ß¼Û ¿¹Á¤  (¼­¿ï½Ã °­³²±¸ »ï¼º·Î 512)
  • ¹«·á¹è¼Û
ÁÖ¹®¼ö·®
°¨¼Ò Áõ°¡
  • À̺¥Æ®/±âȹÀü

  • ¿¬°üµµ¼­

  • »óÇ°±Ç

AD

Ã¥¼Ò°³

¢º ÀÌ Ã¥Àº ¼Òµ¿¹° ÇǺÎÇÐÀ» ´Ù·é À̷м­ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦ 1Æí ÃÑ·Ð 1
1. ÇǺÎÀÇ ±¸Á¶¿Í ±â´É 1
Karen L. Campbell, DVM, MS, DACVIM, DACVD / Carol A. Lichtensteiger, DVM, PhD, DACVP
2. ÇǺÎÇÐ ¿ë¾î 10
Karen L. Campbell, DVM, MS, DACVIM, DACVD / Carol A. Lichtensteiger, DVM, PhD, DACVP
3. ÇǺÎÇÐÀÇ Áø´Ü ±â¹ý 20
Paul Bloom, DVM, DABVP, DACVD
4. ÇǺλý°Ë ¾È³»¼­ : º´¸®ÇÐÀÚÀÇ °üÁ¡¿¡¼­ 31
Robert W. Dunstan, DVM, MS, DACVP / Elizabeth A. Mauldin, DVM, DACVP, DACVD /
Gary M. Davenport, PhD Kelly / M. Credille, DVM, PhD, DACVP

Á¦ 2Æí ÇǺΰú Ä¡·á 41
5. °¡·Á¿òÁõ¿¡ ´ëÇÑ °ü¸® 41
Paul Bloom, DVM, DABVP, DACVP
6. Ç×±ÕÁ¦ Ä¡·á 54
Jan A. Hall, BVM&S, MS, MRCVS, DACVD
7. ÇǺÎÇп¡¼­ÀÇ ±¸ÃæÁ¦ 61
Robert Kennis, DVM, DACVD
8. ¸é¿ªº¸°­Á¦ Ä¡·á(immunoadjuvant therapy) 67
Karen L. Campbell, DVM, MS, DACVIM, DACVD
9. ±¹¼ÒÀû Ä¡·áÀÇ ¿ø¸® 69
Randall C. Thomas, DVM, DACVD
10. ÇǺÎÇп¡¼­ÀÇ ·¹ÀÌÀú 83
Mona Boord, DVM, DACVD

Á¦ 3Æí ¼±ÃµÀû ÀÌ»ó 89
11. °¢È­ ÀÌ»ó 89
Karen A. Kuhl, DVM, DACVD
12. Åаú ÅÐ ¼ºÀåÀÇ ÀÌ»ó 97
Daniel O. Morris, DVM, DACVD
13. Äݶó°Õ°ú ¿¤¶ó½ºÆ¾ÀÇ ¹®Á¦ 103
Jennifer L. Matousek, DVM, MS, DACVD
14. ¼±ÃµÀûÀÎ ¼öÆ÷¼º Áúȯ 110
Christine A. Rees, DVM, DACVD
15. ¿©·¯ °¡Áö ¼±ÃµÀû ȤÀº À¯ÀüÀû Áúȯ 117
Jennifer L. Matousek, DVM, MS, DACVD

Á¦ 4Æí ±â»ýÃ漺 ÇǺÎÁúȯ 125
16. ÀýÁöµ¿¹° ±â»ýÃæ 125
Robert Kennis, DVM, DACVD
17. °ïÃæ 131
Cecilia A. Friberg, DVM, DACVD
18. ¿¬Ã漺 ÇǺκ´(Helminth dermatoses) 137
Randall C. Thomas, DVM, DACVD

Á¦ 5Æí °¨¿°¼º ÇǺÎÁúȯ 143
19. ¼¼±Õ¼º °¨¿° 143
Jennifer L. Matousek, DVM, MS, DACVD
20. Ç¥À缺 Áø±Õ °¨¿° 158
Karen A. Moriello, DVM, DACVD
21. ½ÉÀ缺 Áø±Õ °¨¿° 171
Karen L. Campbell, DVM, MS, DACVIM, DACVD
22. Pythiosis¿Í Lagenidiosis 179
Rosanna Marsella, DVM, DACVD
23. ±âŸ °¨¿°Áõ 184
Jennifer L. Matousek, DVM, MS, DACVD

Á¦ 6Æí ¿°Áõ¼º ÇǺÎÁúȯ 191
24. ¾ÆÅäÇÇ 191
Pascal Prelaud, DV, DECVD
25. À½½Ä °ú¹ÎÁõ 199
Stephanie R. Bruner, DVM, DACVD
26. Á¢Ã˼º °ú¹Î¹ÝÀÀ(contact hypersensitivity) 205
Rosanna Marsella, DVM, DACVD
27. º­·è ¾Ë·¯Áö ÇǺο° 212
Diane E. Bevier, DVM, DACVD
28. ¼Ó¸³(Á¼½Ò)¼º ÇǺο° 218
Diane E. Bevier, DVM, DACVD
29. °í¾çÀÌ È£»ê±¸¼º À°¾ÆÁ¾ º¹ÇÕü 225
Christine A. Rees, DVM, DACVD
30. °³ È£»ê±¸¼º Á¾±âÁõ 230
Dennis W. Crow, DVM, DACVD
31. Ư¹ß¼º ¹«±Õ¼º À°¾ÆÁ¾°ú ³ó¼º À°¾ÆÁ¾ ÁõÈıº 233
Dennis W. Crow, DVM, DACVD
32. ¸é¿ª¸Å°³¼º ÇǺΠÁúȯ 236
Sheila Torres, DVM, MS, PhD, DACVD
33. ´ÙÇüÈ«¹Ý°ú µ¶¼ºÇ¥ÇDZ«»ç¿ëÇØ 249
Jan A. Hall, BVM&S, MS, MRCVS, DACVD
34. Áö¹æÃþ¿°(Panniculitis) 256
Adam P. Patterson, DVM
35. Ç÷°ü¿°°ú Ç÷°üº´Áõ 260
Daniel O. Morris, DVM, DACVD

Á¦ 7Æí ÇǺμҰßÀ» ³ªÅ¸³»´Â ³»ºÐºñ¿Í ´ë»ç¼º Áúȯ 267
36. °©»ó¼± ±â´ÉÀÌ»ó 267
Manon Paradis, DVM, MVSc, DACVD
37. ºÎ½Å ±â´ÉÀÌ»ó 276
Karen L. Campbell, DVM, MS, DACVIM, DACVD
38. ¼º È£¸£¸ó ÇǺÎÁúȯ 288
Linda A. Frank, MS, DVM, DACVD
39. ±âŸ È£¸£¸ó ¹ÝÀÀ¼º Å»¸ðÁõ 296
Manon Paradis, DVM, MVSc, DACVD
40. ´ë»ç¼º ¿ÜÇÇ ±«»çÁõ 306
Stephanie R. Bruner, DVM, ACVD
41. ºÎÁ¾¾ç ÇǺΠÁúȯ 310
Jennifer L. Matousek, DVM, MS, DACVD
42. ¾Æ¿¬(zinc) °ü·Ã¼º ÇǺÎÁõ 314
Rod A.W. Rosychuk, DVM, DACVIM

Á¦ 8Æí ´Ù¾çÇÑ ¿øÀÎÀÇ ÇǺÎÁúȯ 323
43. ȯ°æ¼º ÇǺÎÁúȯ 323
Rod A.W. Rosychuk, DVM, DACVIM
44. ½ÉÀμº ÇǺÎÁúȯ 335
Adam P. Patterson, DVM
45. ¹ßÅé°ú ¹ßÅé ±âÀúºÎÀÇ Áúȯ 343
John C. Angus, DVM, DACVD
46. Ç×¹®ÁÖÀ§ ´©°ü Áúȯ 352
Steven L. Marks, BVSc, MS, MRCVS, DACVIM
47. ¾È°Ë¿° 356
Ralph E. Hamor, DVM, MS, DACVO
48. »ö¼ÒÀÌ»ó 364
Laura B. Stokking, PhD, DVM / Karen L. Campbell, DVM, MS, DACVIM, DACVD
49. ±ÍÀÇ Áúȯ 374
John C. Angus, DVM, DACVD

Á¦ 9Æí ÇǺÎÁ¾¾ç 395
50. ºñ½Å»ý¹°¼º Á¾¾ç 395
Thomas O. Manning, DVM, MS, DACVD Brett C. Wood, DVM
51. »óÇÇ ½Å»ý¹° 404
Laura B. Stokking, PhD, DVM
52. ºÎ¼Ó±â ±â¿øÀÇ Á¾¾ç 415
Thomas O. Manning, DVM, MS, DACVD / Brett C. Wood, DVM
xi
53. °³¿Í °í¾çÀÌÀÇ ÇÇºÎ¿Í ÇÇÇÏÁ¶Á÷ÀÇ Áß°£¿± ½Å»ý¹° Áúȯ 425
Timothy M. Fan, DVM, DACVIM
54. °³¿Í °í¾çÀÌÀÇ ÇǺΠºñ¸¸¼¼Æ÷ ½Å»ý¹° 433
Timothy M. Fan, DVM, DACVIM
55. ¸²ÇÁ Á¶Á÷±¸¼º Á¾¾ç 439
John C. Angus, DVM, DACVD / Louis-Philippe de Lorimier, DVM, DACVM
56. ¸á¶ó´Ñ ¼¼Æ÷ Á¾¾ç 458
Laura B. Stokking, PhD, DVM
57. ¿©·¯ °¡Áö Á¾·ùÀÇ ÇǺÎÁ¾¾ç 469
Brett C. Wood, DVM / Thomas O. Manning, DVM, MS, DACVD

ÀúÀÚ¼Ò°³

Karen L. Campbell [Àú] ½ÅÀ۾˸² SMS½Åû
»ý³â¿ùÀÏ -

ÇØ´çÀÛ°¡¿¡ ´ëÇÑ ¼Ò°³°¡ ¾ø½À´Ï´Ù.

¹Ú¼ºÁØ [¿ª] ½ÅÀ۾˸² SMS½Åû
»ý³â¿ùÀÏ -

ÇØ´çÀÛ°¡¿¡ ´ëÇÑ ¼Ò°³°¡ ¾ø½À´Ï´Ù.

Àü°øµµ¼­/´ëÇб³Àç ºÐ¾ß¿¡¼­ ¸¹Àº ȸ¿øÀÌ ±¸¸ÅÇÑ Ã¥

    ¸®ºä

    0.0 (ÃÑ 0°Ç)

    100ÀÚÆò

    ÀÛ¼º½Ã À¯ÀÇ»çÇ×

    ÆòÁ¡
    0/100ÀÚ
    µî·ÏÇϱâ

    100ÀÚÆò

    0.0
    (ÃÑ 0°Ç)

    ÆǸÅÀÚÁ¤º¸

    • ÀÎÅÍÆÄÅ©µµ¼­¿¡ µî·ÏµÈ ¿ÀǸ¶ÄÏ »óÇ°Àº ±× ³»¿ë°ú Ã¥ÀÓÀÌ ¸ðµÎ ÆǸÅÀÚ¿¡°Ô ÀÖÀ¸¸ç, ÀÎÅÍÆÄÅ©µµ¼­´Â ÇØ´ç »óÇ°°ú ³»¿ë¿¡ ´ëÇØ Ã¥ÀÓÁöÁö ¾Ê½À´Ï´Ù.

    »óÈ£

    (ÁÖ)±³º¸¹®°í

    ´ëÇ¥ÀÚ¸í

    ¾Èº´Çö

    »ç¾÷ÀÚµî·Ï¹øÈ£

    102-81-11670

    ¿¬¶ôó

    1544-1900

    ÀüÀÚ¿ìÆíÁÖ¼Ò

    callcenter@kyobobook.co.kr

    Åë½ÅÆǸž÷½Å°í¹øÈ£

    01-0653

    ¿µ¾÷¼ÒÀçÁö

    ¼­¿ïƯº°½Ã Á¾·Î±¸ Á¾·Î 1(Á¾·Î1°¡,±³º¸ºôµù)

    ±³È¯/ȯºÒ

    ¹ÝÇ°/±³È¯ ¹æ¹ý

    ¡®¸¶ÀÌÆäÀÌÁö > Ãë¼Ò/¹ÝÇ°/±³È¯/ȯºÒ¡¯ ¿¡¼­ ½Åû ¶Ç´Â 1:1 ¹®ÀÇ °Ô½ÃÆÇ ¹× °í°´¼¾ÅÍ(1577-2555)¿¡¼­ ½Åû °¡´É

    ¹ÝÇ°/±³È¯°¡´É ±â°£

    º¯½É ¹ÝÇ°ÀÇ °æ¿ì Ãâ°í¿Ï·á ÈÄ 6ÀÏ(¿µ¾÷ÀÏ ±âÁØ) À̳»±îÁö¸¸ °¡´É
    ´Ü, »óÇ°ÀÇ °áÇÔ ¹× °è¾à³»¿ë°ú ´Ù¸¦ °æ¿ì ¹®Á¦Á¡ ¹ß°ß ÈÄ 30ÀÏ À̳»

    ¹ÝÇ°/±³È¯ ºñ¿ë

    º¯½É ȤÀº ±¸¸ÅÂø¿À·Î ÀÎÇÑ ¹ÝÇ°/±³È¯Àº ¹Ý¼Û·á °í°´ ºÎ´ã
    »óÇ°À̳ª ¼­ºñ½º ÀÚüÀÇ ÇÏÀÚ·Î ÀÎÇÑ ±³È¯/¹ÝÇ°Àº ¹Ý¼Û·á ÆǸÅÀÚ ºÎ´ã

    ¹ÝÇ°/±³È¯ ºÒ°¡ »çÀ¯

    ·¼ÒºñÀÚÀÇ Ã¥ÀÓ ÀÖ´Â »çÀ¯·Î »óÇ° µîÀÌ ¼Õ½Ç ¶Ç´Â ÈÑ¼ÕµÈ °æ¿ì
    (´ÜÁö È®ÀÎÀ» À§ÇÑ Æ÷Àå ÈѼÕÀº Á¦¿Ü)

    ·¼ÒºñÀÚÀÇ »ç¿ë, Æ÷Àå °³ºÀ¿¡ ÀÇÇØ »óÇ° µîÀÇ °¡Ä¡°¡ ÇöÀúÈ÷ °¨¼ÒÇÑ °æ¿ì
    ¿¹) È­ÀåÇ°, ½ÄÇ°, °¡ÀüÁ¦Ç°(¾Ç¼¼¼­¸® Æ÷ÇÔ) µî

    ·º¹Á¦°¡ °¡´ÉÇÑ »óÇ° µîÀÇ Æ÷ÀåÀ» ÈѼÕÇÑ °æ¿ì
    ¿¹) À½¹Ý/DVD/ºñµð¿À, ¼ÒÇÁÆ®¿þ¾î, ¸¸È­Ã¥, ÀâÁö, ¿µ»ó È­º¸Áý

    ·½Ã°£ÀÇ °æ°ú¿¡ ÀÇÇØ ÀçÆǸŰ¡ °ï¶õÇÑ Á¤µµ·Î °¡Ä¡°¡ ÇöÀúÈ÷ °¨¼ÒÇÑ °æ¿ì

    ·ÀüÀÚ»ó°Å·¡ µî¿¡¼­ÀÇ ¼ÒºñÀÚº¸È£¿¡ °üÇÑ ¹ý·üÀÌ Á¤ÇÏ´Â ¼ÒºñÀÚ Ã»¾àöȸ Á¦ÇÑ ³»¿ë¿¡ ÇØ´çµÇ´Â °æ¿ì

    »óÇ° Ç°Àý

    °ø±Þ»ç(ÃâÆÇ»ç) Àç°í »çÁ¤¿¡ ÀÇÇØ Ç°Àý/Áö¿¬µÉ ¼ö ÀÖÀ½

    ¼ÒºñÀÚ ÇÇÇغ¸»ó
    ȯºÒÁö¿¬¿¡ µû¸¥ ¹è»ó

    ·»óÇ°ÀÇ ºÒ·®¿¡ ÀÇÇÑ ±³È¯, A/S, ȯºÒ, Ç°Áúº¸Áõ ¹× ÇÇÇغ¸»ó µî¿¡ °üÇÑ »çÇ×Àº ¼ÒºñÀÚºÐÀïÇØ°á ±âÁØ (°øÁ¤°Å·¡À§¿øȸ °í½Ã)¿¡ ÁØÇÏ¿© 󸮵Ê

    ·´ë±Ý ȯºÒ ¹× ȯºÒÁö¿¬¿¡ µû¸¥ ¹è»ó±Ý Áö±Þ Á¶°Ç, ÀýÂ÷ µîÀº ÀüÀÚ»ó°Å·¡ µî¿¡¼­ÀÇ ¼ÒºñÀÚ º¸È£¿¡ °üÇÑ ¹ý·ü¿¡ µû¶ó ó¸®ÇÔ

    (ÁÖ)KGÀ̴Ͻýº °áÁ¦´ë±Ý¿¹Ä¡¾÷ µî·Ï¹øÈ£: 02-006-00013

    (ÁÖ)ÀÎÅÍÆÄÅ©Ä¿¸Ó½º´Â ȸ¿ø´ÔµéÀÇ ¾ÈÀü°Å·¡¸¦ À§ÇØ ±¸¸Å±Ý¾×, °áÁ¦¼ö´Ü¿¡ »ó°ü¾øÀÌ (ÁÖ)ÀÎÅÍÆÄÅ©Ä¿¸Ó½º¸¦ ÅëÇÑ
    ¸ðµç °Å·¡¿¡ ´ëÇÏ¿© (ÁÖ)KGÀ̴Ͻýº°¡ Á¦°øÇÏ´Â ±¸¸Å¾ÈÀü¼­ºñ½º¸¦ Àû¿ëÇÏ°í ÀÖ½À´Ï´Ù.
    µî·Ï ¿©ºÎ´Â e-±ÝÀ¶¹Î¿ø¼¾ÅÍ È¨ÆäÀÌÁö(www.fcsc.kr)ÀÇ µî·Ï¡¤½Å°í>ÀüÀÚ±ÝÀ¶¾÷µî·ÏÇöȲ ¸Þ´º¿¡¼­ È®ÀÎÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù. ¼­ºñ½º °¡ÀÔ»ç½Ç È®ÀÎ

    ¹è¼Û¾È³»

    • ±³º¸¹®°í »óÇ°Àº Åùè·Î ¹è¼ÛµÇ¸ç, Ãâ°í¿Ï·á 1~2Àϳ» »óÇ°À» ¹Þ¾Æ º¸½Ç ¼ö ÀÖ½À´Ï´Ù.

    • Ãâ°í°¡´É ½Ã°£ÀÌ ¼­·Î ´Ù¸¥ »óÇ°À» ÇÔ²² ÁÖ¹®ÇÒ °æ¿ì Ãâ°í°¡´É ½Ã°£ÀÌ °¡Àå ±ä »óÇ°À» ±âÁØÀ¸·Î ¹è¼ÛµË´Ï´Ù.

    • ±ººÎ´ë, ±³µµ¼Ò µî ƯÁ¤±â°üÀº ¿ìü±¹ Åù踸 ¹è¼Û°¡´ÉÇÕ´Ï´Ù.

    • ¹è¼Ûºñ´Â ¾÷ü ¹è¼Ûºñ Á¤Ã¥¿¡ µû¸¨´Ï´Ù.

    • - µµ¼­ ±¸¸Å ½Ã 15,000¿ø ÀÌ»ó ¹«·á¹è¼Û, 15,000¿ø ¹Ì¸¸ 2,500¿ø - »óÇ°º° ¹è¼Ûºñ°¡ ÀÖ´Â °æ¿ì, »óÇ°º° ¹è¼Ûºñ Á¤Ã¥ Àû¿ë